Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
04/2000
04/06/2000WO2000018899A2 Angiotensin converting enzyme homolog and its use
04/06/2000WO2000018804A1 Tie2 agonist antibodies
04/06/2000WO2000018801A2 Ncam binding compounds
04/06/2000WO2000018768A1 Novel salts of pyridopyrazine compound and crystals thereof
04/06/2000WO2000018762A1 Thrombin inhibitors
04/06/2000WO2000018760A1 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders
04/06/2000WO2000018759A1 Phenylalanine derivatives as alpha 4 integrin inhibitors
04/06/2000WO2000018758A1 Pyrimidone derivatives
04/06/2000WO2000018744A1 Oxazole compounds as prostaglandin e2 agonists or antagonists
04/06/2000WO2000018734A1 Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
04/06/2000WO2000018733A1 Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals
04/06/2000WO2000018724A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY
04/06/2000WO2000018723A1 Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
04/06/2000WO2000018721A1 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
04/06/2000WO2000018438A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof
04/06/2000WO2000018437A1 Tie2 antagonist antibodies
04/06/2000WO2000018424A1 Use of substances with oxytocin activity in order to create cell regeneration
04/06/2000WO2000018421A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions
04/06/2000WO2000018418A2 Inhibition of erythrocyte sickling by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
04/06/2000WO2000018409A1 Use of certain drugs for treating nerve root injury
04/06/2000WO2000018405A1 Use of prostanoid antagonists for the treatment of primary headache disorders
04/06/2000WO2000018397A1 Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
04/06/2000WO2000018395A1 Method for preventing or delaying catheter-based revascularization
04/06/2000WO2000018393A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
04/06/2000WO2000018381A1 Use of epinastine as antitussivum
04/06/2000WO2000018352A2 A method for treating inflammatory diseases by administering a thrombin inhibitor
04/06/2000WO2000018212A2 Platelet-derived growth factor c, dna coding therefor, and uses thereof
04/06/2000WO2000002572A9 Inclusion of apoptotic regulators in solutions for cell storage at low temperature
04/06/2000WO2000001835A3 Targeted integration into chromosomes using retroviral vectors
04/06/2000WO2000001704A3 Benzimidazoles, production thereof and use thereof as medicaments
04/06/2000WO2000001671A3 Antihistaminic piperidine derivatives and intermediates for the preparation thereof
04/06/2000WO1999066936A9 Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
04/06/2000WO1999066054A3 Erythropoietin analog-human serum albumin fusion protein
04/06/2000WO1999065476A3 COMPOSITIONS FOR INCREASING ENERGY $i(IN VIVO)
04/06/2000WO1999064596A3 Proteins regulating gene expression
04/06/2000WO1999064585A3 Novel angiotensin receptor, production and use thereof
04/06/2000WO1999064421A8 Acetylcholine enhancers
04/06/2000WO1999061626A3 Human hydrolase homologs: n-terminal asparagine amidohydrolase, glycosyl hydrolase, glucohydrolase, biotinidase, and n-acetylglucosamine 6-p deacetylase
04/06/2000WO1999061468A3 The induction of antibiotic peptides by lait (scd14) protein
04/06/2000WO1999061013A3 COMPOUNDS HAVING IgE AFFECTING PROPERTIES
04/06/2000WO1999059608A3 Osteoporosis treatment
04/06/2000WO1999058699A3 Transgenic plant-derived human blood coagulation factors
04/06/2000WO1999057144A3 Human transcriptional regulator molecules
04/06/2000WO1999054706A3 Method of treating interstitial cystitis with recombinant hb-egf
04/06/2000WO1999052858A3 Lipids
04/06/2000WO1999046284A3 Molecules that home to various selected organs or tissues
04/06/2000WO1999045907A3 Metal chelators for use in the treatment of alzheimer's disease
04/06/2000WO1999037294A3 Mitochondria protecting agents for treating mitochondria associated diseases
04/06/2000CA2714449A1 Use of certain drugs for treating nerve root injury
04/06/2000CA2345988A1 Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
04/06/2000CA2345641A1 A method for treating inflammatory diseases by administering a thrombin inhibitor
04/06/2000CA2345474A1 Oxazole compounds as prostaglandin e2 agonists or antagonists
04/06/2000CA2345362A1 Novel salts of pyridopyrazine compound and crystals thereof
04/06/2000CA2345243A1 Inhibition of erythrocyte sickling by n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester
04/06/2000CA2345108A1 Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
04/06/2000CA2345066A1 Identifying agents that alter mitochondrial permeability transition pores
04/06/2000CA2345065A1 Pyrimidone derivatives
04/06/2000CA2344561A1 Platelet-derived growth factor c, dna coding therefor, and uses thereof
04/06/2000CA2344457A1 Slgp protein and nucleic acid molecule and uses therefor
04/06/2000CA2344274A1 Angiotensin converting enzyme homolog and its use
04/06/2000CA2343975A1 Ncam binding compounds
04/06/2000CA2343939A1 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
04/06/2000CA2343922A1 Use of specific hybrid promoters for controlling tissue expression
04/06/2000CA2343716A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions
04/06/2000CA2343696A1 Membrane-associated organizational proteins
04/06/2000CA2343109A1 Thrombin inhibitors
04/06/2000CA2342981A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
04/06/2000CA2342622A1 New substituted indolinones,their preparation and their use as medicaments
04/06/2000CA2338442A1 Phenylalanine derivatives as alpha 4 integrin inhibitors
04/06/2000CA2311462A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof
04/06/2000CA2285151A1 Novel heparin binding peptides
04/05/2000EP0990442A1 Therapeutic treatment for chronic myeloid leukemia and active lymphoid leukemia
04/05/2000EP0990037A2 Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
04/05/2000EP0990034A1 Anti-gpiib/iiia recombinant antibodies
04/05/2000EP0990031A2 Tumor necrosis factor receptor 5
04/05/2000EP0990002A1 Dextran derivatives, preparation method and applications as medicine with specific biological action
04/05/2000EP0989995A2 Torsin, torsin genes, and methods of use
04/05/2000EP0989987A1 Spiro-azacyclic derivatives and their use as therapeutic agents
04/05/2000EP0989986A1 5,7-disubstituted 4-aminopyrido 2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors
04/05/2000EP0989985A1 Fused polycyclic 2-aminopyrimidine derivatives as protein kinase inhibitors
04/05/2000EP0989984A1 Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
04/05/2000EP0989983A1 Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
04/05/2000EP0989982A1 Barbituric acid derivatives with antimetastatic and antitumor activity
04/05/2000EP0989981A1 Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
04/05/2000EP0989977A1 Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors)
04/05/2000EP0989975A1 Oxazole compounds useful as pge2 agonists and antagonists
04/05/2000EP0989973A1 Chalcones having antiproliferative activity
04/05/2000EP0989859A1 Cns neuroregenerative compositions and methods of use
04/05/2000EP0989858A1 Cd28/ctla-4 inhibiting peptidomimetics, pharmaceutical compositions thereof, and method of using same
04/05/2000EP0989857A1 Novel therapeutic agents that modulate enzymatic processes
04/05/2000EP0989853A1 Self-regulated apoptosis of inflammatory cells by gene therapy
04/05/2000EP0989850A1 Use of pramipexole in the treatment of restless legs syndrome
04/05/2000EP0989849A2 Therapeutic nanospheres
04/05/2000EP0777740B1 Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle
04/05/2000EP0777739B1 Genetic therapy of vascular diseases with a cell-specific active substance which is dependent on the cell cycle
04/05/2000EP0766664B1 Metalloproteinase inhibitors
04/05/2000EP0765308B1 Enzyme inhibitors
04/05/2000EP0750631B1 Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
04/05/2000EP0734371B1 Novel retinoid conjugate compounds and methods for treating skin aging
04/05/2000EP0716661B1 Pseudo- and non-peptide bradykinin receptor antagonists
1 ... 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 ... 1564